

Quartal News Report

April-June 2026



ELPA MEMBERSHIP NETWORK CONTINUES TO GROW

Welcome

Alpha1-MZ Foundation



Netherlands



Together, we continue to
strengthen the voice of people
living with liver disease
across Europe.

PODCAST

Talk Show

Check them out!

Dr Stan Driessen

Small Steps, Big Changes!- Fueling your Liver: The Nutrition Episode

Dr Willy Theel

Small Steps Big Changes-Beyond Weight loss: The Science of Movement and Liver Health in MASLD & MASH

Prof. Dr. Manuel Romero Gomez

The Importance of Healthy Lifestyle for Liver Patients

Prof. Shira Zelber-Sagi

Food, Health and Real Life

Prof. Dr. van Rossum

Understanding the Obesity-MASLD Link

Understanding the obesity-Insights from lived experiences

Josip Kresović

Breaking the Habit

Integrating Real-World Data into EMA and EU/National HTA

ICONIC Voices - Listening as Science: Building Meaningful Advocacy in Liver Health



ELPA Screening Tour – France, Cyprus, and Germany

As part of the European Liver Screening Tour 2026, France hosted the first stops of ELPA's major awareness and prevention initiative aimed at promoting early detection of liver disease across Europe. **The French leg of the tour took place in Charleville from April 16–19, 2026**, offering free, non-invasive liver health screenings to the public and raising awareness about the growing burden of liver disease. The initiative, organised by the European Liver Patients' Association (ELPA) in collaboration with the local association SOS Hépatite Champagne-Ardenne, forms part of a wider European campaign travelling across six countries in 2026.

The second stop was in Cyprus, from May 7-11, 2026, during the country's Presidency of the Council of the European Union. Organised in collaboration with the ELPA member Promitheas, the event in Cyprus received strong institutional support, including the participation of the Minister of Health and Member of the European Parliament Hadjipantela, whose presence underscored the growing recognition of liver health as a public health priority at both national and European levels.

The Münster stop of the ELPA Liver Screening Tour (June 9 to 11, 2026) marked the third stop of the 2026 tour in Germany, following successful activities in France and Cyprus. Organised by ELPA in close partnership with Universitätsklinikum Münster (UKM) and its hepatology team, the screening activities combined early detection with practical education on liver disease prevention, risk factors, and healthy lifestyles.

In each country, media coverage highlighted strong public engagement, with healthcare professionals, patient advocates, and volunteers supporting screening activities and educational outreach. The Screening Tour also reinforces ELPA's broader advocacy efforts calling for liver health to become an integral part of European prevention strategies.

EPF 2026 Annual General Meeting

The European Patients' Forum (EPF) held its 2026 Annual General Meeting (AGM) on April 18, 2026 in Brussels, gathering representatives from patient organisations across Europe to discuss the future of patient advocacy, healthcare resilience, and organisational leadership.

A major highlight of this year's AGM was the appointment of Valentina Strammiello as Executive Director of EPF, following her interim leadership period. The appointment reflects EPF's continued commitment to strengthening patient-centred advocacy and reinforcing the role of patients in shaping European health policy.

During the meeting, members reviewed EPF's strategic priorities for the coming years, focusing on:

- **equitable access to healthcare,**
- **medicine shortages,**
- **prevention and early detection,**
- **digital health and AI integration,**
- **mental health burden of chronic diseases,**
- **and stronger collaboration among patient organisations across Europe.**

The AGM also marked an important step in the development of EPF's upcoming Strategic Plan 2027–2031, with member organisations contributing recommendations for the organisation's future vision and mission. Consultations and drafting activities are expected to continue throughout 2026.



World Hepatitis Summit 2026

The World Hepatitis Summit (WHS) 2026 took place from April 28–30, 2026 in Bangkok, Thailand, bringing together global health experts, policymakers, clinicians, civil society organisations, and patient advocates to accelerate progress toward hepatitis elimination.

Organised by the World Hepatitis Alliance, the summit focused on the theme “Elimination for everyone, everywhere, right now!” and highlighted the urgent need for stronger political commitment and patient-centred action.

ELPA was strongly represented at the summit, with many members and representatives attending sessions, networking events, and advocacy discussions alongside international stakeholders. The active participation of ELPA members once again demonstrated the organisation’s commitment to ensuring that the patient voice remains central in global hepatitis and liver health policies.

A special highlight was the poster presentation delivered by Ivana Dragojević, ELPA Vice-President and Treasurer, who presented her work and advocacy efforts in the field of liver disease prevention and patient engagement. Ivana Dragojević is widely recognised for her longstanding contribution to hepatitis advocacy and patient representation at both European and international level.

The summit provided an important platform for discussing:

- viral hepatitis elimination strategies,
- equitable access to testing and treatment,
- liver cancer prevention,
- integration of hepatitis services into healthcare systems,
- and the importance of community-led and patient-driven approaches.

With fewer than five years remaining to achieve the WHO hepatitis elimination targets, WHS 2026 reinforced the need for stronger collaboration between governments, healthcare professionals, and patient organisations.

On April 30, 2026, the European Association for the Study of the Liver (EASL) officially launched the EASL–Lancet Commission 2.0 in Brussels under the title “From Evidence to Impact: Implementing Sustainable Liver Health in Europe.”

The high-level event brought together policymakers, clinicians, researchers, economists, patient organisations, and public health leaders to discuss how scientific evidence can be translated into concrete policy action for liver health across Europe.

The launch focused on the growing burden of liver disease in Europe and the urgent need for stronger prevention, early detection, and integrated care strategies. The Commission builds on the first EASL–Lancet report published in 2021 and aims to accelerate implementation of its recommendations at both EU and national levels.

The new Commission report presents updated evidence showing that liver disease remains one of the few major non-communicable diseases still increasing across Europe. According to the report, cirrhosis and liver cancer are responsible for nearly 780 deaths every day in the WHO European Region, while liver cancer mortality has increased by more than 50% since 2000.

ELPA played an important role in the discussions, reinforcing the patient perspective and advocating for faster implementation of policies that improve outcomes for people living with liver disease. Speaking during the launch activities, ELPA President Marko Korenjak stressed the importance of moving “from words to action” to ensure earlier diagnosis and equitable care for patients across Europe.



New EASL– Lancet Commission 2.0 Officially Launched in Brussels

GRIPonMASH Annual Meeting 2026



The [GRIPonMASH](#) Annual Meeting 2026 successfully concluded in Rome, Italy, bringing together consortium partners for two days of productive exchange, scientific discussion, and cross-disciplinary collaboration focused on advancing innovation in MASLD/MASH research. Held on April 16–17, 2026, the meeting gathered experts and stakeholders from across the consortium to review progress achieved during the project's third year and strengthen alignment on the next phases of implementation. The event provided an important platform for consortium-wide reflection and coordination across all work packages. **Discussions covered a broad range of topics, including:**

- **early detection and screening strategies,**
- **biomarker development,**
- **decision-support tools,**
- **patient-centred approaches,**
- **digital innovation,**
- **and integrated pathways for MASLD/MASH management.**

The strong engagement and collaborative spirit demonstrated throughout the meeting reflected the strength of the GRIPonMASH multidisciplinary partnership and its shared commitment to addressing the growing burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Partners highlighted the importance of maintaining a coherent and coordinated approach as the project moves forward, ensuring that scientific advances are translated into practical tools and solutions capable of improving patient outcomes and supporting healthcare systems across Europe.

ELPA AGM, new Member, and Training



Alongside the EASL Congress 2026 in Barcelona from 27–30 May 2026, ELPA successfully held its Annual General Meeting (AGM) and a series of dedicated training sessions, bringing together patient advocates and member organisations from across Europe to strengthen collaboration, build capacity, and advance the patient voice in hepatology.

The AGM provided an important opportunity for ELPA members to review ongoing activities, discuss strategic priorities, and reinforce joint efforts to improve the lives of people living with liver diseases. Delegates exchanged experiences, shared best practices, and explored new opportunities for collaboration across Europe. **The meeting also welcomed a new member organization, the Alpha1 MZ Foundation from the Netherlands, further strengthening ELPA's growing network and representation of liver patients across the continent.**

A key component of the Barcelona programme was a series of educational training sessions designed to empower patient representatives with the latest scientific knowledge and advocacy tools. Participants attended an **in-depth training on the evolving role of GLP-1 receptor agonists in hepatology**, exploring their impact on obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and the future of integrated liver care. In addition, a **dedicated session focused on Alpha-1 Antitrypsin Deficiency (Alpha-1)**, highlighting the challenges faced by people living with this rare genetic liver disease. The programme also featured an interactive workshop dedicated to the **ICONIC Project**, where participants contributed to the validation of patient skills and competencies developed through the project.

New Publication Highlights the Importance of “Listening-Informed Policies” in Population Health

Advocacy

The act of pleading or arguing
for something, such
as of something, such
as of something, such

A new viewpoint article published in Health Expectations explores how lived patient experience can become a stronger and more structured form of evidence in health policy and prevention strategies.

Titled “From Participation to Evidence: Listening-Informed Policies and the Epistemic Role of Lived Experience in Population Health,” the publication was developed in collaboration between researchers from the University of Pavia, the Catholic University of the Sacred Heart, and the European Liver Patients’ Association (ELPA).

The article introduces the concept of Listening-Informed Policies (LIP), arguing that listening to patients and communities should go beyond consultation and become an integral part of evidence-based health governance. Using liver health as a practical example, the authors demonstrate how patient experiences can help identify barriers to prevention, stigma, delayed diagnosis, and inequalities in access to care.

The publication also highlights ELPA’s contribution in translating lived experiences into policy-relevant insight, particularly in advocating for the inclusion of MASLD within broader cardiovascular and prevention strategies at EU level.

Co-authored by Serena Barelo, Michela Monaci, Sarah Bigi, Beatrice Credi, and Marko Korenjak, the paper reinforces the growing recognition of patient organisations as key partners in shaping more equitable, responsive, and effective healthcare policies.

EASL Congress 2026



ELPA actively participated in EASL Congress 2026, held in Barcelona, Spain, from May 27–30, 2026.

As Europe's leading congress dedicated to liver health, the event brought together thousands of healthcare professionals, researchers, industry partners, policymakers, and patient advocates from around the world to discuss the latest advances in hepatology and liver disease care. Throughout the congress, ELPA reinforced the importance of ensuring that the patient perspective remains at the centre of research, policy development, and clinical practice. The event provided valuable opportunities to engage with key stakeholders across the liver community, strengthen existing collaborations, and contribute to discussions on improving outcomes for people living with liver diseases. **A particular highlight was the active involvement of ELPA representatives in congress activities and stakeholder discussions, demonstrating the growing recognition of patients as essential partners in liver health research and care.** Through these exchanges, ELPA continued to advocate for better prevention, earlier diagnosis, equitable access to treatment, and improved quality of life for patients across Europe.



European Congress on Obesity 2026

ELPA was pleased to participate in the 33rd European Congress on Obesity (ECO 2026), held in Istanbul, Türkiye, from May 12–15, 2026.

ECO is Europe's leading scientific congress dedicated to obesity research, prevention, and management, bringing together healthcare professionals, researchers, policymakers, and patient representatives from across the continent. **During the congress, ELPA presented a poster highlighting the achievements and impact of the European Liver Screening Week 2025 campaign. The poster attracted considerable interest from congress participants, providing an opportunity to discuss the importance of integrating liver health into broader obesity prevention and management strategies.** As obesity and metabolic-associated liver disease continue to represent major public health challenges, ELPA's participation at ECO 2026 reinforced the need for multidisciplinary collaboration and early screening initiatives to improve patient outcomes. The congress highlighted the growing recognition that liver health is an essential component of comprehensive obesity care.

FOR STEATOTIC LIVER DISEASE

The Hidden NCD as the
next Global Public Health Priority




On May 21, 2026, ELPA participated in a high-level policy event held in Geneva on the sidelines of the 79th World Health Assembly (WHA79).

The event, "Together for Steatotic Liver Disease – The Hidden NCDs: SLD as the Next Global Public Health Priority," was co-hosted by the Global Liver Institute (GLI) and the Egyptian Ministry of Health and Population, bringing together Ministers of Health, government representatives, international organisations, clinicians, researchers, civil society leaders, and patient advocates from around the world. **ELPA was represented by its Director, Milan Mishkovikj, who joined discussions on the growing global burden of Steatotic Liver Disease (SLD) and the urgent need to strengthen prevention, early diagnosis, and access to care.** The event provided an important platform to ensure the patient perspective was reflected in international policy discussions and to highlight the real-life impact of liver disease on millions of people worldwide. The meeting took place at a historic moment for the liver community. The dialogue was organised in support of the draft resolution on Steatotic Liver Disease that was under consideration by Member States during the World Health Assembly. Participants explored how global commitments could be translated into concrete national actions, including the integration of liver health into national non-communicable disease (NCD) strategies, improved screening programmes, and stronger public awareness initiatives. The adoption of the WHO Resolution on Steatotic Liver Disease later during the Assembly marked a major milestone for liver health advocacy. For the first time, SLD was formally recognised within the global NCD framework, acknowledging its strong links with obesity, diabetes, cardiovascular disease, and other metabolic conditions. The resolution calls on governments to strengthen prevention, early detection, surveillance, and integrated care pathways while promoting research and health system preparedness.



DECISION Project: Discover the Full Video Series on Key Research Findings

DECISION Project Publishes New Video Series on Key Research Findings



The DECISION project has successfully completed and published a new video series presenting some of its key research findings in an accessible and engaging format.

Developed with contributions from researchers across the consortium, the series translates complex scientific results into short videos aimed at clinicians, general practitioners, researchers, and interested members of the public. The series includes expert contributions on topics such as single-cell insights in liver disease, DNA methylation in cirrhosis progression, translational animal models for MASLD/MASH, extracellular vesicles in acute liver decompensation, emergency granulopoiesis in liver failure, and the ClustALL approach to stratifying patients with decompensated cirrhosis. By making these findings available in a clear and concise video format, DECISION strengthens the communication of research beyond the academic community and supports knowledge sharing among healthcare professionals, researchers, and wider audiences.

The full playlist is available [here](#).



HL4EU Final Conference

ELPA participated in the HL4EU Final Conference – Advancing Cross-Sector Collaboration for a Healthier Europe, held at the European Parliament Info Hub in Brussels on May 4, 2026.

The event marked the conclusion of the Erasmus+ funded Healthy Lifestyles for Europe (HL4EU) project, in which ELPA was a partner with organisations from the health, physical activity, mobility, patient, and community sectors. The conference was the occasion to present the project's achievements and discuss future pathways for cross-sector collaboration. A key outcome of the event was the launch of the HL4EU Policy Recommendations, developed through extensive research, analysis of good practices from across Europe, and stakeholder engagement activities. Throughout the conference, speakers highlighted the importance of integrating health promotion, physical activity, and disease prevention into wider public policies. Presentations showcased findings from the project's database of 136 good practices, explored barriers and enablers to collaboration across sectors, and examined how evidence can be translated into effective policy action. As the voice of liver patients in Europe, ELPA welcomed the project's strong emphasis on prevention and health literacy. Liver diseases share many common risk factors with other non-communicable diseases, including obesity, metabolic disorders, and unhealthy lifestyles. **Strengthening health literacy and empowering citizens to make informed health decisions are essential components of effective prevention strategies and improved health outcomes.** ELPA is proud to have contributed to the discussions and looks forward to building on the project's legacy by continuing to advocate for stronger health literacy, healthier lifestyles, and better outcomes for people living with liver diseases across Europe.

HTA Stakeholder Network Meeting



On June 23, 2026, ELPA participated in the HTA Stakeholder Network Meeting organised by the European Commission in Brussels.

The meeting brought together stakeholder organisations to discuss the ongoing implementation of the EU Health Technology Assessment Regulation and its impact on patients, healthcare professionals, HTA bodies, and health systems. According to the 2026 HTA Annual Work Programme, the Stakeholder Network will continue to support dialogue with the HTA Coordination Group, including through two face-to-face meetings in June and October. **For ELPA, the meeting was an important opportunity to underline the need for meaningful patient involvement in EU-level HTA processes, particularly in joint clinical assessments and joint scientific consultations. Ensuring that patient perspectives are included early, consistently, and transparently is essential to make assessments more relevant to real-life needs and to support timely and equitable access to innovation.** ELPA will continue to contribute to the HTA Stakeholder Network, advocating for stronger patient engagement, clearer processes for identifying and involving patient experts, and recognition of lived experience as an essential part of evidence-based decision-making.

Cancer Patient Europe Annual Meetings



From June 24–26, 2026, ELPA participated in the Cancer Patients Europe (CPE) Annual Meeting in Brussels, held under the theme "Protecting and Improving Europe's Cancer Care Model in a Changing World."

The three-day event brought together cancer patient organisations, policymakers, clinicians, researchers, industry representatives, and European institutions to discuss the future of cancer care and strengthen patient-centred policies across Europe. The meeting opened with an Institutional Policy Event at the European Committee of the Regions, focusing on the role of regional authorities in reducing inequalities in access to cancer care across Europe. **This was followed by the CPE Annual Conference, which explored key policy priorities including clinical trials, equitable access to cancer care, personalised medicine, shared decision-making, innovation, and the implementation of major EU health initiatives such as the HTA Regulation and the Pharmaceutical Strategy.** The event concluded with the CPE Annual General Assembly, where members reviewed the organisation's activities, governance, and strategic priorities for the coming years. For ELPA, participation provided an important opportunity to strengthen collaboration with fellow European patient organisations and contribute to discussions on integrated care, prevention, equitable access to innovation, and meaningful patient involvement in health policy. As liver disease and cancer share many common risk factors—including metabolic dysfunction, obesity, viral hepatitis, and alcohol-related harm—ELPA continues to advocate for liver health to be fully integrated into Europe's broader cancer prevention and care agenda. Strengthening collaboration across disease areas remains essential to improving health outcomes and ensuring that patient voices continue to shape European healthcare policies.



20th anniversary of EMA's Patients' and Consumers' Working Party (PCWP)

ELPA representatives took part in the 20th Anniversary of the European Medicines Agency's (EMA) Patients' and Consumers' Working Party (PCWP), on June 30, 2026, celebrating two decades of structured patient engagement in the European medicines regulatory system.

The anniversary event reflected on the achievements of patient involvement in medicines regulation and looked ahead to the future of meaningful collaboration among regulators, patients, healthcare professionals, and other stakeholders. The celebration formed part of the broader PCWP/HCPWP meeting held on 30 June–1 July 2026, bringing together patient organisations, healthcare professionals, EMA leadership, and representatives of the Agency's scientific committees to discuss the next generation of patient engagement in medicines development and regulation. ELPA was proud to be represented at this milestone event, reaffirming its long-standing commitment to ensuring that the lived experience of people living with liver disease continues to shape regulatory decision-making and the development of safe, effective, and patient-centred medicines across Europe.

ELPA Liver Disease Prevention Village 2026



From June 1 to 5, 2026, the European Liver Patients' Association (ELPA) transformed the Esplanade of the European Parliament in Brussels into a vibrant hub for health promotion with the ELPA Liver Disease Prevention Village.

The Prevention Village represented an important evolution of ELPA's commitment to bringing liver health directly to citizens. Rather than waiting for people to seek healthcare, ELPA brought prevention into one of Europe's busiest public spaces, creating a unique environment where science, policy, healthcare professionals, patient organisations, and the public came together around one shared goal: preventing liver disease before it is too late. Throughout the five-day event, visitors had the opportunity to receive free, non-invasive liver health assessments, learn about the major risk factors for liver disease, and speak directly with healthcare professionals and patient advocates. The initiative also provided practical advice on healthy lifestyles, early detection, and when to seek medical follow-up, helping to improve health literacy while reducing the stigma that still surrounds liver disease. The Prevention Village reflected the growing recognition that liver health cannot be addressed in isolation. Liver disease is closely linked with obesity, diabetes, cardiovascular disease, kidney disease, cancer, and viral hepatitis. **To illustrate these connections, ELPA created an interactive prevention pathway in collaboration with a multidisciplinary network of partners. Visitors moved through six themed stations dedicated to liver screening (Liver4Life), body composition (ELPA), diabetes prevention (International Diabetes Federation Europe – IDF Europe), cardiovascular disease prevention (Federación Española del Hígado), cancer prevention (Cancer Patients Europe), and viral hepatitis testing (SOS Hépatites Champagne-Ardenne).** Together, these organisations demonstrated that protecting liver health requires an integrated approach to preventing and managing non-communicable diseases, with patients, healthcare professionals, and policymakers working side by side. The timing of the event was particularly significant. Just days earlier, WHO Member States had adopted a landmark Resolution on reducing the global burden of liver disease, reinforcing the urgent need to prioritise liver health within the wider non-communicable disease agenda. At the European level, ELPA continues to advocate for liver health to be fully integrated into key policy initiatives, including the upcoming EU Safe Hearts Plan and Europe's Beating Cancer Plan.



High-Level Event: Liver Health in the EU Public Health Agenda: Acting Earlier to Prevent Cardio-Renal-Hepatic-Metabolic Diseases – The Case of MASLD

On June 3, 2026, ELPA convened a high-level policy roundtable at the European Parliament in Brussels.

The event brought together policymakers, patient leaders, clinicians, researchers, international organisations, and public health experts to advance the integration of liver health into Europe's non-communicable disease (NCD) agenda. Hosted by MEP Nikos Papandreou (S&D, Greece) and MEP Michalis Hadjipantela (EPP, Cyprus), the event focused on the growing burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and its close links with cardiovascular, renal, and metabolic diseases. Entitled "Liver Health in the EU Public Health Agenda: Acting Earlier to Prevent Cardio-Renal-Hepatic-Metabolic Diseases – The Case of MASLD", the discussion highlighted the urgent need to recognise liver disease as a public health priority rather than a condition managed solely within hepatology. Participants stressed that MASLD is often the first visible sign of broader metabolic dysfunction, providing a unique opportunity for earlier intervention before complications develop. The roundtable was deliberately aligned with key international and European policy developments, including the recently adopted WHO Resolution on Steatotic Liver Disease (SLD) and the emerging European Safe Heart Plan, reinforcing the importance of integrated approaches across liver, cardiovascular, renal, and metabolic health. **Throughout the discussions, speakers emphasised that prevention, early detection, and multidisciplinary care should become central pillars of future EU health policies.** The programme featured four thematic panels covering the full patient pathway—from prevention and risk identification to integrated care and policy implementation. Contributions came from representatives of the World Health Organization Regional Office for Europe, the European Association for the Study of the Liver (EASL), IDF Europe, United European Gastroenterology (UEG), leading academic institutions, healthcare professionals, and patient organisations. Topics included community-based screening, primary care pathways, integrated management of cardio-renal-hepatic-metabolic diseases, and the translation of scientific evidence into effective public health policy.

LEOPARD Annual General Meeting



On June 18–19, 2026, ELPA participated in the LEOPARD Second Annual Meeting, joining partners from across Europe to review progress and shape the next phase of this Horizon Europe research project dedicated to improving liver transplantation through artificial intelligence.

Over two days of intensive discussions and collaborative working sessions, consortium partners assessed achievements across the project and aligned on the roadmap for the months ahead. Key topics included data harmonisation, multimodal analytics, predictive modelling, OMICs integration, radiomics, clinical validation, and strategies to ensure high-quality data for future implementation. The meeting also highlighted the importance of stakeholder and patient engagement throughout the research process. As the patient organisation representing people living with liver disease across Europe, ELPA continues to play a key role in ensuring that patients' perspectives help shape the development of innovative tools and future clinical applications. The LEOPARD project aims to harness artificial intelligence to improve decision-making in liver transplantation, supporting more accurate patient prioritisation and ultimately contributing to better transplant outcomes across Europe. **The productive discussions in Valencia reinforced the value of multidisciplinary collaboration between clinicians, researchers, technology developers, and patient organisations. Together, the consortium established a clear roadmap for the coming months, bringing the project one step closer to translating cutting-edge research into real benefits for patients awaiting liver transplantation. More on the project [here](#).**

ARTEMIS layperson event


The ARTEMIS EU Project was proudly presented to ELPA members at the EASL Congress 2026, sparking engaging discussions about its objectives, innovations, and the future of Digital Twins in liver healthcare.

The patient perspective emerged as a key focus, generating many insightful questions from participants. A special ELPA-organized event featured outstanding presentations from leading experts, including Prof. Irene Vignon-Clementel (Inria), a pioneer in Digital Human Twins, Dr. Raluca Pais (Pitié-Salpêtrière Hospital, Paris), and Prof. Juan Manuel Pericàs (Vall d'Hebron University Hospital). The event was moderated by ELPA President Marko Korenjak. **More on the project [here](#).**





ELPA on social Media





Marko Korenjak
ELPA President



As representatives of people affected by liver cancer, we see every day the devastating toll this disease takes on patients and their families. Too often, liver cancer is linked to Hepatitis B, a virus that is preventable through vaccination, making many cases of liver cancer entirely avoidable. No one should face a life-threatening diagnosis when effective prevention exists. This World Immunisation Week, **we call for stronger commitment to Hepatitis B vaccination** as a cornerstone of cancer prevention in Europe. Expanding access to vaccines means saving lives and reducing suffering - and we will not stop advocating until prevention is made a true priority.

#WorldImmunisationWeek

European Liver Patients' Association @EuropeLiver · 19 May
Europe is entering a new era in healthcare — and #liverhealth must be at the heart of it.

#Hepatitis B, C and D are not just #infectious diseases. They are among the leading causes of #livercancer in Europe.

But today, for the first time in history, we have the tools to change
[Show more](#)



8 9 575



European Liver Patients' Association @EuropeLiver · 19 Apr

This #WorldLiverDay, it's time to turn awareness into action.

While ELPA's "Small Steps, Big Changes" podcast empowers you with expert knowledge, we're also taking prevention directly to the people.

🇪🇺 🇫🇷 🇮🇹, the #EuropeanLiverScreeningTour is on the ground—bringing free

[Show more](#)



SMALL STEPS, BIG CHANGES TALKS

Tune in to ELPA's "Small Steps, Big Changes" podcast series, where we share knowledge, support and empower patient communities—because solid habits build a strong liver!



Dr. Willy Theel MPA
Session Assistant, PhD Candidate



Stan Driessen MD
PhD Candidate



Josip Kresović
Health Psychologist



Prof. Dr. Manuel Romero Gomez
Director UCM Digestive Diseases



Prof. Shira Zelber-Sagi
Clinical nutritionist, researcher, and educator

HERA and 9 others

ELPA supports its members, stakeholders, supporters and friends' campaigns



Fatty Liver Awareness Day (month) 2026



European Liver Patients' Association @EuropeLiver · 11 Jun
#FattyLiverDay #FattyLiverMonth #MASHDay #SLDAwarenessDay

Today, on this important day dedicated to raising awareness of Steatotic Liver Disease (SLD), ELPA's Leader of the SLD Working Group, Yiannoula Koulla, has the honour of addressing this crucial global health challenge
[Show more](#)



1

3

3


371



PROTECT LIVER HEALTH, PROTECT PUBLIC HEALTH.



Awareness today. Healthier lives tomorrow.



Did you know?!



Lower socioeconomic status is associated with a higher prevalence of liver disease risk factors, including SLD (Steatotic Liver Disease).



Health inequalities can increase the risk of delayed diagnosis and limited access to liver care.



Early detection and equal access to screening can help save lives.

- ✓ Know your risk.
- ✓ Get screened.
- ✓ Protect your liver.
- ✓ Protect your future.

♥ Your Liver. Your Health. Your Future.

#LiverHealth #SLD #MASLD #EarlyDetection #PublicHealth #HealthEquity #ELPA



ELPA

European Liver
Patients' Association

TOGETHER
We are
STRONGER



ELPA's aim is to promote the interests of people with liver disease and in particular: to highlight the size of the problem; to promote awareness and prevention; to address the low profile of liver disease as compared to other areas of medicine such as heart disease; to share experience of successful initiatives; to work with professional bodies such as EASL and with the EU to ensure that treatment and care are harmonized across Europe to the highest standards.

www.elpa.eu

office@elpa.eu

+32 (0) 4 78155224

